Harbour Investments’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.85K Sell
213
-12
-5% -$319 ﹤0.01% 3622
2026
Q1
$6.03K Buy
225
+57
+34% +$1.71K ﹤0.01% 3506
2025
Q4
$5.17K Hold
168
﹤0.01% 3001
2025
Q3
$5.15K Buy
168
+35
+26% +$853 ﹤0.01% 2971
2025
Q2
$2.75K Hold
133
﹤0.01% 3044
2025
Q1
$2.6K Hold
133
﹤0.01% 3016
2024
Q4
$2.78K Hold
133
﹤0.01% 2922
2024
Q3
$3.24K Buy
133
+7
+6% +$187 ﹤0.01% 2777
2024
Q2
$3.17K Hold
126
﹤0.01% 2676
2024
Q1
$3.77K Hold
126
﹤0.01% 2596
2023
Q4
$4.01K Sell
126
-25
-17% -$785 ﹤0.01% 2495
2023
Q3
$5.33K Hold
151
﹤0.01% 2250
2023
Q2
$5.74K Buy
151
+25
+20% +$997 ﹤0.01% 2237
2023
Q1
$4.76K Sell
126
-24
-16% -$923 ﹤0.01% 2291
2022
Q4
$6.36K Buy
150
+126
+525% +$5.19K ﹤0.01% 2147
2022
Q3
$1K Hold
24
﹤0.01% 2578
2022
Q2
$1K Buy
+24
New +$778 ﹤0.01% 2578
2021
Q4
$1K Sell
24
-11
-31% -$459 ﹤0.01% 2508
2021
Q3
$2K Sell
35
-99
-74% -$4.44K ﹤0.01% 3304
2021
Q2
$5K Buy
134
+99
+283% +$3.82K ﹤0.01% 3047
2021
Q1
$1K Buy
+35
New +$1.32K ﹤0.01% 3387

Other funds holding GMAB

Harbour Investments's GMAB Position: Q2 2026 in Review

Harbour Investments reduced its Genmab (GMAB) stake by 5.3% in Q2 2026, selling an estimated $319 and leaving 213 shares worth $5.85K. The position accounts for ﹤0.01% of the portfolio, ranked #3622.

Harbour Investments first reported a position in GMAB in Q1 2021 and has held it in 21 quarters since. The position peaked at $6.36K in Q4 2022. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Harbour Investments held 213 shares of Genmab worth $5.85K as of Q2 2026.
  • Harbour Investments sold 12 Genmab shares in Q2 2026, an estimated $319.
  • Genmab made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3622 holding.
  • Harbour Investments first reported a position in Genmab in Q1 2021 and has held it in 21 quarters since.
  • Harbour Investments's Genmab position peaked at $6.36K in Q4 2022.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.